139 related articles for article (PubMed ID: 19295247)
1. Second-line therapy in refractory pancreatic cancer. results of a phase II study.
Pelzer U; Stieler J; Roll L; Hilbig A; Dörken B; Riess H; Oettle H
Onkologie; 2009 Mar; 32(3):99-102. PubMed ID: 19295247
[TBL] [Abstract][Full Text] [Related]
2. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.
Tsavaris N; Kosmas C; Skopelitis H; Gouveris P; Kopterides P; Loukeris D; Sigala F; Zorbala-Sypsa A; Felekouras E; Papalambros E
Invest New Drugs; 2005 Aug; 23(4):369-75. PubMed ID: 16012797
[TBL] [Abstract][Full Text] [Related]
3. 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma.
Assaf E; Verlinde-Carvalho M; Delbaldo C; Grenier J; Sellam Z; Pouessel D; Bouaita L; Baumgaertner I; Sobhani I; Tayar C; Paul M; Culine S
Oncology; 2011; 80(5-6):301-6. PubMed ID: 21778770
[TBL] [Abstract][Full Text] [Related]
4. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group.
Pelzer U; Schwaner I; Stieler J; Adler M; Seraphin J; Dörken B; Riess H; Oettle H
Eur J Cancer; 2011 Jul; 47(11):1676-81. PubMed ID: 21565490
[TBL] [Abstract][Full Text] [Related]
5. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer.
Yoo C; Hwang JY; Kim JE; Kim TW; Lee JS; Park DH; Lee SS; Seo DW; Lee SK; Kim MH; Han DJ; Kim SC; Lee JL
Br J Cancer; 2009 Nov; 101(10):1658-63. PubMed ID: 19826418
[TBL] [Abstract][Full Text] [Related]
6. PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy.
Gill S; Ko YJ; Cripps C; Beaudoin A; Dhesy-Thind S; Zulfiqar M; Zalewski P; Do T; Cano P; Lam WYH; Dowden S; Grassin H; Stewart J; Moore M
J Clin Oncol; 2016 Nov; 34(32):3914-3920. PubMed ID: 27621395
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas.
Olszewski AJ; Grossbard ML; Chung MS; Chalasani SB; Malamud S; Mirzoyev T; Kozuch PS
J Gastrointest Cancer; 2013 Jun; 44(2):182-9. PubMed ID: 23208490
[TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin plus 5-fluorouracil and folinic acid (OFF) in gemcitabine-pretreated advanced pancreatic cancer: a phase II study.
El-Hadaad HA; Wahba HA
J Gastrointest Cancer; 2013 Sep; 44(3):313-7. PubMed ID: 23606201
[TBL] [Abstract][Full Text] [Related]
9. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.
Kozuch P; Grossbard ML; Barzdins A; Araneo M; Robin A; Frager D; Homel P; Marino J; DeGregorio P; Bruckner HW
Oncologist; 2001; 6(6):488-95. PubMed ID: 11743211
[TBL] [Abstract][Full Text] [Related]
10. Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas.
Araneo M; Bruckner HW; Grossbard ML; Frager D; Homel P; Marino J; DeGregorio P; Mortazabi F; Firoozi K; Jindal K; Kozuch P
Cancer Invest; 2003; 21(4):489-96. PubMed ID: 14533437
[TBL] [Abstract][Full Text] [Related]
11. 5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy.
Lee MG; Lee SH; Lee SJ; Lee YS; Hwang JH; Ryu JK; Kim YT; Kim DU; Woo SM
Chemotherapy; 2013; 59(4):273-9. PubMed ID: 24457620
[TBL] [Abstract][Full Text] [Related]
12. Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: a Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study.
Janinis J; Papakostas P; Samelis G; Skarlos D; Papagianopoulos P; Fountzilas G
Ann Oncol; 2000 Feb; 11(2):163-7. PubMed ID: 10761750
[TBL] [Abstract][Full Text] [Related]
13. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer.
Hwang IG; Jang JS; Oh SY; Rho MH; Lee S; Park YS; Park JO; Nam EM; Lee HR; Jun HJ; Chi KC
Cancer Chemother Pharmacol; 2015 Apr; 75(4):757-62. PubMed ID: 25677446
[TBL] [Abstract][Full Text] [Related]
15. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial.
Oettle H; Riess H; Stieler JM; Heil G; Schwaner I; Seraphin J; Görner M; Mölle M; Greten TF; Lakner V; Bischoff S; Sinn M; Dörken B; Pelzer U
J Clin Oncol; 2014 Aug; 32(23):2423-9. PubMed ID: 24982456
[TBL] [Abstract][Full Text] [Related]
16. Concomitant administration of weekly oxaliplatin, fluorouracil continuous infusion, and radiotherapy after 2 months of gemcitabine and oxaliplatin induction in patients with locally advanced pancreatic cancer: a Groupe Coordinateur Multidisciplinaire en Oncologie phase II study.
Moureau-Zabotto L; Phélip JM; Afchain P; Mineur L; André T; Vendrely V; Lledo G; Dupuis O; Huguet F; Touboul E; Balosso J; Louvet C
J Clin Oncol; 2008 Mar; 26(7):1080-5. PubMed ID: 18309942
[TBL] [Abstract][Full Text] [Related]
17. Complete remission of metastatic pancreatic cancer with cardiac involvement after gemcitabine, oxaliplatin and 46-h infusion of 5-fluorouracil/leucovorin.
Wu WC; Chen SC; Su YC; Chuang WL; Chen LT
J Gastroenterol Hepatol; 2004 Jun; 19(6):716-7. PubMed ID: 15151634
[No Abstract] [Full Text] [Related]
18. Biweekly triple combination chemotherapy with gemcitabine, oxaliplatin, levofolinic acid and 5-fluorouracil (GOLF) is a safe and active treatment for patients with inoperable pancreatic cancer.
Correale P; Montagnani F; Miano S; Sciandivasci A; Pascucci A; Petrioli R; Testi W; Tanzini G; Francini G
J Chemother; 2008 Feb; 20(1):119-25. PubMed ID: 18343754
[TBL] [Abstract][Full Text] [Related]
19. A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma.
Correale P; Messinese S; Caraglia M; Marsili S; Piccolomini A; Petrioli R; Ceciarini F; Micheli L; Nencini C; Neri A; Vuolo G; Guarnieri A; Abbruzzese A; Prete SD; Giorgi G; Francini G
Br J Cancer; 2004 May; 90(9):1710-4. PubMed ID: 15150625
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine (GEM) plus oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX-4) in patients with advanced gastric cancer.
Correale P; Fulfaro F; Marsili S; Cicero G; Bajardi E; Intrivici C; Vuolo G; Carli AF; Caraglia M; Del Prete S; Greco E; Gebbia N; Francini G
Cancer Chemother Pharmacol; 2005 Dec; 56(6):563-8. PubMed ID: 16041610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
